From our inception it’s been our mission to investigate, uncover and present new data and knowledge to better our understanding and use of cannabis. With that ethos in mind we continually reinvest in clinical studies and research
CiiTECH Labs is a new initiative of CiiTECH, together with key researcher, Professor Yossi Tam from The Hebrew University. The aim is to further our Cannabis research and know-how, from current and previous studies, in developing indication specific formulations.
In 2017 we began two projects, the first investigating the potential for CBD to treat Asthma with Professor Raphael Mechoulam and Professor Levi Shaffer. The second study looked at the potential to treat fatty liver disease.
A study into the Therapeutic Effect of CBD for obesity induced Non-alcoholic Fatty Liver Disease (NAFLD)
Dr. Yossi Tam, DMD, PhD, Obesity and Metabolism Laboratory
The project is uniquely poised to address the therapeutic potential of phytocannabinoids in ameliorating fat accumulation in hepatocytes, as well as to define the molecular mechanisms underlying their role in the development of NAFLD. The research has led the development and clinical testing of phytocannabinoids for the treatment of fatty liver in humans and patent pending formulations.
A study to identify a possible inhibitory effect of a CBD derivative to inhibit Allergic Airway Inflammation / Asthma
Professor Raphael Mechoulam & Professor Francesaca Levi-Schaffer
The purpose of the study is to study the effect of CBD on AAI and whether it has the potential to directly downregulate the pro-inflammatory functions of MCs and Eos.
This was the first study to assess CBD on human mast cells and eosinophils and in a mouse model of asthma that closely resembles the human disease.
Following the completion of these experiments, we will know whether our cannabinoid will affect the AAI and whether it has the potential to directly downregulate the pro-inflammatory functions of MCs and Eos.